Enhanced Antitumor Activity of Murine-human Hybrid T-cell Receptor (TCR) in Human Lymphocytes is Associated with Improved Pairing and TCR/CD3 Stability

Overview

Journal Cancer Res

Specialty Oncology

Date 2006 Sep 5

PMID 16951205

Citations 249

Authors

Cyrille J Cohen

Yangbing Zhao

Zhili Zheng

Steven A Rosenberg

Richard A Morgan

Affiliations

Soon will be listed here.

Abstract

Little is known about the biology of murine T-cell receptors (TCR) expressed in human cells. We recently observed that a murine anti-human p53 TCR is highly functional when expressed in human lymphocytes. Herein, we compare human and mouse TCR function and expression to delineate the molecular basis for the apparent superior biological activity of murine receptors in human T lymphocytes. To this end, we created hybrid TCRs where we swapped the original constant regions with either human or mouse ones, respectively. We showed that murine or "murinized" receptors were overexpressed on the surface of human lymphocytes compared with their human/humanized counterparts and were able to mediate higher levels of cytokine secretion when cocultured with peptide-pulsed antigen-presenting cells. Preferential pairing of murine constant regions and improved CD3 stability seemed to be responsible for these observations. These enhanced biological properties translated into significantly greater antitumor response mediated by TCR with mouse constant regions. Furthermore, we were able to circumvent the natural low avidity of class I MHC TCR in CD4(+) cells by introducing the murinized TCR into CD4(+) lymphocytes, giving them the ability to recognize melanoma tumors. These findings have implications for human TCR gene transfer therapy and may provide new insights into the biology of the TCR/CD3 complex.

Citing Articles

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy.

Hsu M, Willimsky G, Hansmann L, Blankenstein T Front Immunol. 2025; 16:1518691.

PMID: 39931057 PMC: 11807957. DOI: 10.3389/fimmu.2025.1518691.

Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.

Chih Y, Dietsch A, Koopmann P, Ma X, Agardy D, Zhao B Nat Commun. 2025; 16(1):1262.

PMID: 39893177 PMC: 11787355. DOI: 10.1038/s41467-025-56547-w.

Identification of novel KRAS neoantigen specific TCRs and a strategy to eliminate off-target recognition.

Han X, Han X, Hao Y, Wang B, Li L, Chen S J Transl Med. 2025; 23(1):78.

PMID: 39819441 PMC: 11740425. DOI: 10.1186/s12967-025-06094-1.

Utilization of primary tumor samples for cancer neoantigen discovery.

Leko V, Groh E, Levi S, Copeland A, White B, Gasmi B J Immunother Cancer. 2025; 13(1.

PMID: 39800378 PMC: 11748769. DOI: 10.1136/jitc-2024-010993.

Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.

Semilietof A, Stefanidis E, Gray-Gaillard E, Pujol J, DEsposito A, Reichenbach P J Immunother Cancer. 2025; 12(12.

PMID: 39794936 PMC: 11667476. DOI: 10.1136/jitc-2024-009504.

References

Willemsen R, Weijtens M, Ronteltap C, Eshhar Z, Gratama J, Chames P . Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 2000; 7(16):1369-77. DOI: 10.1038/sj.gt.3301253. View

Viola A, Lanzavecchia A . T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996; 273(5271):104-6. DOI: 10.1126/science.273.5271.104. View

Stanislawski T, Voss R, Lotz C, Sadovnikova E, Willemsen R, Kuball J . Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001; 2(10):962-70. DOI: 10.1038/ni1001-962. View

Luznik L, Jalla S, Engstrom L, Iannone R, Fuchs E . Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001; 98(12):3456-64. DOI: 10.1182/blood.v98.12.3456. View

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100. DOI: 10.1126/science.1068440. View

Schumacher T . T-cell-receptor gene therapy. Nat Rev Immunol. 2002; 2(7):512-9. DOI: 10.1038/nri841. View

Chames P, Willemsen R, Rojas G, Dieckmann D, Rem L, Schuler G . TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol. 2002; 169(2):1110-8. DOI: 10.4049/jimmunol.169.2.1110. View

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

Ho W, Yee C, Greenberg P . Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002; 110(10):1415-7. PMC: 151827. DOI: 10.1172/JCI17214. View

10.

Rubinstein M, Kadima A, Salem M, Nguyen C, Gillanders W, Nishimura M . Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003; 170(3):1209-17. DOI: 10.4049/jimmunol.170.3.1209. View

11.

Morgan R, Dudley M, Yu Y, Zheng Z, Robbins P, Theoret M . High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003; 171(6):3287-95. PMC: 2248799. DOI: 10.4049/jimmunol.171.6.3287. View

12.

Cohen C, Denkberg G, Lev A, Epel M, Reiter Y . Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit. 2003; 16(5):324-32. DOI: 10.1002/jmr.640. View

13.

Boulter J, Glick M, Todorov P, Baston E, Sami M, Rizkallah P . Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 2003; 16(9):707-11. DOI: 10.1093/protein/gzg087. View

14.

Call M, Pyrdol J, Wucherpfennig K . Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum. EMBO J. 2004; 23(12):2348-57. PMC: 423287. DOI: 10.1038/sj.emboj.7600245. View

15.

Zhang T, He X, Tsang T, Harris D . Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther. 2004; 11(7):487-96. DOI: 10.1038/sj.cgt.7700703. View

16.

Appay V . The physiological role of cytotoxic CD4(+) T-cells: the holy grail?. Clin Exp Immunol. 2004; 138(1):10-3. PMC: 1809194. DOI: 10.1111/j.1365-2249.2004.02605.x. View

17.

Teixeiro E, Daniels M, Hausmann B, Schrum A, Naeher D, Luescher I . T cell division and death are segregated by mutation of TCRbeta chain constant domains. Immunity. 2004; 21(4):515-26. DOI: 10.1016/j.immuni.2004.08.014. View

18.

Salter R, Howell D, Cresswell P . Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985; 21(3):235-46. DOI: 10.1007/BF00375376. View

19.

Topalian S, Solomon D, Rosenberg S . Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989; 142(10):3714-25. View

20.

Saito T, Sussman J, Ashwell J, Germain R . Marked differences in the efficiency of expression of distinct alpha beta T cell receptor heterodimers. J Immunol. 1989; 143(10):3379-84. View